Inventaire - arkadaşlarınız ve topluluklarınız en iyi kitaplığınızdır

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

yazar

Jennifer R Gatchel

Bernard J Hanseeuw

Aaron P. Schultz

Paul S. Aisen

Rebecca E. Amariglio

yayınlandığı: Alzheimer's and Dementia

yayımlanma tarihi: 2017-02-27

main subject: Alzheimer hastalığı

Cites articles 39

Date

Başlık

Yazarlar

2016-09-01

Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia

Peter J. Snyder, Pierrick Bourgeat, Yen Ying Lim, Simon M. Laws, Ralph Martins, Robert H Pietrzak, Colin L. Masters, Paul Maruff, Stephanie R Rainey-Smith, Olivier Salvado, Victor L Villemagne, AIBL Research Group
2016-08-29

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

Randall J. Bateman, Tammie L. Benzinger, Anne M Fagan, Eric McDade, Jason Hassenstab, Martin R. Farlow, Stephen Salloway, Katrina L Paumier, Guoqiao Wang, Anna Santacruz, Susan Mills, Lon S Schneider
2016-07-20

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study

Samantha Burnham, Pierrick Bourgeat, Greg Savage, Simon M. Laws, Ralph Martins, Colin L. Masters, Paul Maruff, Olivier Salvado, Victor L Villemagne, AIBL Research Group, Belinda M Brown
2016-04-11

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change

Anja Soldan, Corinne Pettigrew, Marilyn S. Albert
2016-03-01

The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials

Deborah Blacker, Bradley Hyman, Paul S. Aisen, Rebecca E. Amariglio
2016-01-21

Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study
2015-12-12

Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score

Yen Ying Lim, Peter J. Snyder, Pierrick Bourgeat, Ralph Martins, Colin L. Masters, Robert H Pietrzak, Paul Maruff, Olivier Salvado, Victor L Villemagne
2015-11-23

Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease

Aaron P. Schultz, Rebecca E. Amariglio
2015-11-23

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

Ronald C. Petersen, Clifford Jack, David S Knopman, Michelle M Mielke, Val J. Lowe, Mary M Machulda, Heather J Wiste, Stephen Weigand, Rosebud O Roberts, Yonas E Geda, Walter A Rocca, Vernon Pankratz
2015-10-27

Tau positron emission tomographic imaging in aging and early Alzheimer disease

Jorge Sepulcre, Aaron P. Schultz, Reisa Sperling, Bradley Hyman, Rebecca Betensky, Rebecca E. Amariglio, Teresa Gómez-Isla
2015-09-29

CAP--advancing the evaluation of preclinical Alzheimer disease treatments

Randall J. Bateman, Maria C Carrillo, John C. Morris, Eric M. Reiman, Paul S. Aisen, Reisa Sperling, Jessica B Langbaum, Pierre N Tariot, Francisco Lopera
2015-09-05

Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial

Bruno Dubois, Harald Hampel, Bruno Vellas, Pascal Chevalet, Hovagim Bakardjian
2014-11-01

Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals

Aaron P. Schultz, Rebecca Betensky, Rebecca E. Amariglio
2014-08-01

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

Alzheimer's Disease Neuroimaging Initiative, Michael Donohue, Michael W. Weiner, Paul S. Aisen, Reisa Sperling, Rema Raman, Alzheimer’s Disease Cooperative Study
2014-04-21

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

Raj C. Shah, Kewei Chen, David A Bennett, Eric M. Reiman
2014-04-18

Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease

Alzheimer's Disease Neuroimaging Initiative, Andrew Ward, Willem Huijbers, Aaron P. Schultz, Rebecca Betensky
2014-03-01

The A4 study: stopping AD before symptoms begin?

Jason Karlawish, Paul S. Aisen
2013-10-30

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease

Cassandra Szoeke, Paul Maruff, Kathryn A Ellis, Ralph Martins, Colin L. Masters, Robert H Pietrzak, Nicola T Lautenschlager
2013-09-06

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial

Nick C. Fox, William E. Klunk, Randall J. Bateman, Tammie L. Benzinger, William S Brooks, Alison Goate, Martin Rossor, Peter R Schofield, Peter J. Snyder, Anne M Fagan, John C. Morris, Nigel J Cairns, Paul S. Aisen, Reisa Sperling, Richard Mayeux
2013-04-10

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

Mark A. Mintun, David M. Holtzman, John C. Morris, Anne M Fagan, Tammie L. Benzinger, Catherine M Roe, Jason Hassenstab, Courtney L Sutphen, Krista Moulder
2013-03-20

Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia

William E. Klunk, Lewis Kuller
2013-03-13

Regulatory innovation and drug development for early-stage Alzheimer's disease
2013-03-06

Screening for predementia AD: time-dependent operating characteristics of episodic memory tests

Richard B. Lipton, Cuiling Wang, M.J. Katz
2013-02

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

David S Knopman, Ronald C. Petersen, Prashanthi Vemuri, Heather J Wiste, Stephen Weigand, John Q. Trojanowski, Paul S. Aisen, Nathan Pankratz
2012-10-01

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

Alzheimer's Disease Neuroimaging Initiative, Mark A. Mintun, Michael W. Weiner, Ronald C. Petersen, Paul S. Aisen, William J. Jagust, Robert A Koeppe, Abhinay D Joshi
2012-07-11

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study

Mark A. Mintun, Eric M. Reiman, R. Edward Coleman
2012-01-11

Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease

Holger Jahn, Johannes Kornhuber, Jens Wiltfang, Julius Popp, Robert Perneczky, Werner Maier, Michael Wagner, Piotr Lewczuk, Lutz Frölich
2011-01-01

Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments

Kewei Chen, Eric M. Reiman, Kenneth S. Kosik
2011-05

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Laurel A. Beckett, Clifford Jack, Jeffrey Kaye, Yaakov Stern, David A Bennett, Maria C Carrillo, Anne M Fagan, Eric M. Reiman, Kristine Yaffe, Paul S. Aisen, Reisa Sperling, Eric R Siemers, Suzanne Craft, Marcelle Morrison-Bogorad, Creighton H Phelps, Thomas J Montine
2010-07-01

Free and cued selective reminding identifies very mild dementia in primary care

Richard B. Lipton
2009-12-01

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition

Mark A. Mintun, John C. Morris
2008-03-01

Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease

Alan B. Zonderman, Richard B. Lipton, Susan Resnick

Makale - wd:Q38933111

Welcome to Inventaire

arkadaşlarınızın ve topluluklarınızın kütüphanesi

daha fazlasını öğrenin